NourishLife Awarded Exclusive License by Children’s Hospital & Research Center Oakland to Patent for Treatment of Apraxia; a Neurological Disorder

Share Article

NourishLife enters exclusive license agreement with Children’s Hospital & Research Center Oakland to a patented nutritional therapeutic formulation for the treatment of apraxia. Apraxia is a neurological disorder characterized by the inability to perform purposeful motor movements. Verbal apraxia affects the ability to produce normal sounds needed for speech. Estimates are that up to 50% of children with autism spectrum disorders have verbal apraxia, although not all children with apraxia have autism.

The anecdotal evidence reported by a large number of parents is encouraging. Of course, we cannot expect this formulation to help every child. But it appears that a significant percentage of these children being supplemented with an omega-3/antioxidant cocktail are experiencing positive results

NourishLife announced today that it has entered into an exclusive license agreement with CHRCO (Children’s Hospital & Research Center Oakland) to a patented nutritional therapeutic formulation designed for the treatment of apraxia.

Apraxia is a neurological disorder characterized by the inability to perform purposeful motor movements, despite having the desire and physical ability to perform the movements. Verbal apraxia affects the ability to produce normal sounds needed for speech. Experts believe the number of cases is increasing in this previously rare condition. It is estimated that up to 50% of children with autism spectrum disorders have verbal apraxia, although not all children with apraxia have autism.

Statement from Dr. Bertram H. Lubin, President, Director of Medical Research, CHORI: “We are very pleased to license our technology to NourishLife. This company has demonstrated a strong commitment to working closely with Dr. Claudia Morris to develop and provide a formulation that will be evaluated for the treatment of children with apraxia. We are very excited about the application of nutritional interventions for children with neurodevelopmental disorders. We believe NourishLife is an ideal partner to commercialize this technology.”

Mark Nottoli, co-founder of NourishLife stated: “The anecdotal evidence reported by a large number of parents is encouraging. Of course, we cannot expect this formulation to help every child. But it appears that a significant percentage of these children being supplemented with an omega-3/antioxidant cocktail are experiencing positive results”.

Dr. Claudia R. Morris, MD, a published researcher, pediatric emergency medicine physician and inventor of the nutritional apraxia cocktail stated: “Verbal apraxia is a serious neurological disorder of unknown etiology that prevents normal speech development. It can occur in isolation but is also commonly found in association with other disorders like autism. We have promising observations of improved speech and coordination from hundreds of parents of children with verbal apraxia when consuming my omega-3/antioxidant-based formulation that warrants validation through controlled clinical trials. I have designed a protocol for an interventional trial that will utilize my patented formulation produced by NourishLife. We are in the process of seeking funding for this important research which should yield credible results suitable for publication in a scientific journal.

Further information is available at speechtrial.com

Nottoli concluded: “We are pleased to be part of this project as it fits in perfectly with the mission and vision of NourishLife. As the father of four children, I am personally thrilled at the prospect of helping children who cannot talk, begin to speak.”

About NourishLife:
NourishLife nourishlife intends to contribute to a major improvement in health and wellness by addressing nutritional deficiencies. The firm expects it work to help significantly reduce healthcare costs. Founded by nutrition industry veterans, the firm employs expert scientists and nutritionists passionate about health.

The PharmaOmega division of NourishLife PharmaOmega is becoming the web's premier source of omega-3 information, research and news. Working with some of the world’s leading research scientists, PharmaOmega creates effective, evidence-based specialty omega 3 nutrition products of the highest concentration, quality and purity.

NourishLife is a privately held company located in the Chicago area.

About CHRCO:
Research at Children’s Hospital & Research Center Oakland, CA
Research efforts at Children’s Hospital & Research Center Oakland are coordinated through Children’s Hospital Oakland Research Institute (CHORI). Children’s Hospital Oakland is Northern California’s only freestanding and independent children’s hospital.

CHORI’s internationally renowned biomedical research facility brings together seven centers of excellence that are devoted to Clinical and basic science research to treat and prevent disease. CHORI has approximately 300 staff members and an annual budget of more than $49 million. The National Institutes of Health is CHORI’s primary funding source. The institute is a leader in translational research, bringing bench discoveries to bedside applications. These include providing cures for blood diseases, developing new vaccines for infectious diseases and discovering new treatment protocols for previously fatal or debilitating conditions such as cancers, sickle cell disease and thalassemia, diabetes, asthma, HIV/AIDS, pediatric obesity, nutritional deficiencies, birth defects, hemophilia and cystic fibrosis.

Press Contact:
Roy Bingham, NourishLife, LLC, 250 E. Deerpath Road, Lake Forest, IL, 60045. Tel: 847 582-1317

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Roy Bingham
Visit website